An Open-Label Extension to a 52-Week Multi-Center Randomized Double-Blind Placebo-Controlled Parallel Group Study in Patients with Mild Alzheimer
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
No Description Available
Description
No Description Available
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
22 Apr 2024.
Study ID: 1010002699 (0909-03)